Drug intelligence / Profile preview

15,16-dihydrotanshinone I

Development stage
Preclinical
Modality
Small Molecules
Administration
Oral (in Herbal/nutritional Preparations), Topical (in Cosmetic Formulations), Experimental (in Vitro/in Vivo Research Applications)
01

Overview

15,16-dihydrotanshinone I is a **bioactive abietane diterpenoid compound** primarily isolated from the roots of *Salvia miltiorrhiza* (Danshen)[1][2][3][4][5]. It has been employed historically in traditional Chinese medicine and is now under investigation for its pharmacological effects: - **Mechanisms of action** include anti-proliferative and anti-inflammatory activities through cell cycle arrest (G0/G1 phase), inhibition of cyclins and cyclin-dependent kinases, upregulation of p21, and modulation of key signaling pathways, notably **AMP-activated protein kinase (AMPK)** activation, and suppression of **Akt/mTOR** and **MAPK** signaling in cancer cells[3][5]. - Demonstrates **antioxidant**, **anti-inflammatory**, **antimicrobial**, and pronounced **anticancer** effects (particularly against various tumor cell lines)[1][2][3][5]. - Also studied for cardiovascular protection, neuroprotection, and skin applications[1][5]. Most data come from preclinical models; definitive human efficacy remains unproven.

Other names
dihydrotanshinone I(-)-dihydrotanshinone Idihydrotanshinone-Itanshinone I, dihydro-15,16-dihydrotanshinone-I (alternative spelling)(1R)-1,6-dimethyl-1,2-dihydronaphtho[1,2-g][1]benzofuran-10,11-dione(1R)-1,6-dimethyl-1,2-dihydrophenanthro[1,2-b]furan-10,11-dionecannabisin A standard
02

Targets

AMPK (Adenosine monophosphate–activated protein kinase)EGFR (Epidermal growth factor receptor)ELAVL1 (Human Antigen R)CTNNB1 (Beta-catenin)AKT (RAC-alpha serine/threonine-protein kinase)CCNA2 (Cyclin A2)CCND1 (Cyclin D1)CCNE1 (Cyclin E1)CDK2 (Cyclin-dependent kinase 2)CDK4 (Cyclin-dependent kinase 4)mTOR (Mammalian target of rapamycin kinase)MEKRB1 (Retinoblastoma-associated Protein)MYC (MYC proto-oncogene protein)CDKN1A (Cyclin-dependent kinase inhibitor 1A)

Beyond the preview

Go deeper on 15,16-dihydrotanshinone I.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on 15,16-dihydrotanshinone I.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call